Novo Nordisk Files First-Ever Dual GLP-1/Amylin Drug for FDA Review

Key Takeaways:

• Novo Nordisk filed the first-ever dual GLP-1/amylin combination drug (CagriSema) with the FDA on December 18, 2024
• CagriSema achieved 23% weight loss in Phase 3 trials, compared to 14.9% for semaglutide alone
• FDA review expected throughout 2025, with potential approval by late 2025 or early 2026
• Manufacturing complexity could affect accessibility and cost compared to current single-ingredient treatments

Novo Nordisk Makes Historic Filing for Dual-Mechanism GLP-1 Drug

Novo Nordisk announced on December 18, 2024, the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for once-weekly CagriSema, a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg, and semaglutide 2.4 mg. This filing marks a watershed moment in obesity treatment, as CagriSema represents the first FDA-reviewed GLP-1 receptor agonist and amylin analogue combination treatment to seek approval.

The drug targets two complementary pathways: CagriSema combines semaglutide, already approved as Wegovy for obesity and Ozempic for diabetes, with cagrilintide, a long-acting amylin analogue. This dual approach addresses weight loss through different mechanisms, potentially offering superior results compared to single-target therapies.

Trial Results Show Superior Weight Loss

In the REDEFINE 1 phase 3 trial, adults with obesity, or overweight with at least one obesity-related complication, taking CagriSema lost an average of 23% body weight when evaluating the treatment effect if all participants stayed on treatment, according to Novo Nordisk's data.

To put this in perspective, participants in the late-phase study lost an average of 20.4% of their body weight after taking CagriSema for 68 weeks, compared to 14.9% with semaglutide, 11.5% with cagrilintide alone and 3% with placebo. The combination clearly outperformed either component alone.

The Redefine 1 trial showed CagriSema led to significant weight loss, with 91.9% achieving ≥5% body weight reduction, compared to 31.5% in the placebo group. These results suggest CagriSema could help people who haven't achieved adequate weight loss with current GLP-1 therapies like Wegovy or Zepbound.

FDA Review Timeline and Approval Pathway

The FDA is expected to review the CagriSema application in 2025, with industry analysts predicting a decision expected in late 2025, meaning that the drug could launch by the end of the year or early 2026.

If approved, CagriSema would provide you and healthcare professionals with an additional treatment option supported by results from the Redefine clinical program, including robust efficacy, high treatment completion rates, and a tolerability profile consistent with its underlying pharmacology, according to Novo Nordisk.

The company has positioned CagriSema as "a meaningful step forward in the holistic treatment of obesity," combining "the well-established profile of semaglutide with a novel mechanism of action."

Competitive Landscape Intensifies

This filing comes as Novo Nordisk faces increasing competition from Eli Lilly. Novo Nordisk's application for CagriSema comes at the same time as competitor Eli Lilly's request for its obesity drug orforglipron. Both companies are racing to bring next-generation weight loss treatments to market.

Novo needs to find a strong competitor to Lilly's drugs. Zepbound's higher efficacy has allowed it to win significant market share, and Lilly is planning to launch a next-generation obesity drug that targets three gut hormones and has promoted more than 28% weight loss in clinical trials.

However, Novo is "pleased" with the 23% weight loss that CagriSema caused, which shows that it offers "clinically meaningful additive weight loss effects" that are superior to what's been seen with drugs that only target GLP-1, including semaglutide, the active ingredient in Novo's existing obesity injection Wegovy.

Manufacturing and Access Challenges

Novo has positioned CagriSema to be a potential successor to Wegovy for obesity, but if the drug is approved, it could face formulation-specific manufacturing challenges. Unlike single-main-ingredient injectables like Wegovy and Zepbound, CagriSema's co-formulation can't be mixed, requiring each to be made separately and placed in a dual-chambered pen.

This manufacturing complexity could affect both production capacity and cost, potentially impacting accessibility for people seeking affordable GLP-1 treatment options. The dual-chambered delivery system may also increase production costs compared to current single-ingredient medications, which could translate to higher prices for consumers and insurance companies.

What This Means for You

CagriSema's potential approval represents a significant advance in obesity treatment, especially if you've reached a weight loss plateau on current GLP-1 medications like Wegovy or Zepbound. The 23% average weight loss seen in trials could provide new hope for people who need more intensive treatment.

However, approval is still at least a year away. If you're currently seeking GLP-1 treatment, you can explore existing options through our comprehensive provider directory. The competitive landscape between Novo Nordisk and Eli Lilly may also drive down costs and improve access to current medications like tirzepatide while we wait for next-generation treatments like CagriSema.

For now, working with healthcare providers to optimize your current treatment approach remains the best path forward. Understanding your medication options can help you make informed decisions about your weight management plan.